|本期目录/Table of Contents|

[1]杨三虎,高红祥,崔立春,等.贝伐珠单抗治疗非小细胞肺癌脑转移伴顽固性瘤周水肿的临床分析[J].中华肺部疾病杂志,2020,(05):676-678.[doi:10.3877/cma.j.issn.1674-6902.2020.05.021]
点击复制

贝伐珠单抗治疗非小细胞肺癌脑转移伴顽固性瘤周水肿的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年05期
页码:
676-678
栏目:
短篇论著
出版日期:
2020-10-20

文章信息/Info

Title:
-
作者:
杨三虎1; 高红祥2; 崔立春2; 畅 婕2; 李 瑶2; 魏 娜2; 杨拴盈3; 杜建飞2
710000 西安,空军(第四)军医大学唐都医院胸外科1 710000 西安,长安医院肿瘤科2 710000 西安,西安交通大学第二附属医院呼吸与重症医学科3
Author(s):
-
关键词:
非小细胞肺癌;  脑转移瘤;  瘤周水肿;  贝伐珠单抗
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2020.05.021
摘要:
-
Abstract:
-

参考文献/References:

1 Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression[J]. Neurosurgery, 1997, 40: 1269-1277.
2 Shotaro M. The Endothelin ETB Receptor Antagonist BQ788 Protects against Brain Edema after Fluid Percussion Injury by Decreasing Vascular Endothelial Growth Factor-A Expression in Mice[J]. Yakugaku Zasshi, 2017, 137(10): 1241-1246.
3 Martin P, Jeeva M, Roger M, et al. Simulating vasogenic brain edema using chronic VEGF infusion[J]. J Neurosurg, 2017, 127(4): 905-916.
4 Nuh NR, Dmitriy K, Joao I, et al. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases[J]. Sci Transl Med, 2016, 8(360): 360ra135.
5 Vaquero J, Zurita M, Oya S. Expression and significance of vascular permeability factor in tumour infiltrating lymphocytes of brain metastases[J]. Acta Neurochir(Wien), 2001, 143(2): 153-157.
6 Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain of edema[J]. Dan Med J, 2013, 60(4): B4626.
7 Zhou C, Wu YL, Chen GY, et al. BEYOND: a randomized, double-
blind, placebo-controlled, multicenter, phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(19): 2197-204.
8 Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006, 355(24): 2542-2550.
9 Shen G, Wang YJ, Guan YJ, et al. Relief effect of bevacizumab on severe edema induced by re-irradiation in brain tumor patients[J]. Chin Med J(Engl), 2015, 128(15): 2126-2129.
10 Ma YF, Zheng CT, Feng YP, et al. Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis[J]. J Craniofac Surg, 2017, 28(6): e569-e571.
11 Karen T, Herbert HE, Konstantin VS, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab[J]. J Neurooncol, 2014, 117(2): 321-327.
12 Javier G, Ashok JK, Charles AC, et al. Effect of bevacizumab on radiation necrosis of the brain[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 323-326.
13 Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience[J]. Ann Oncol, 2012, 23(2): 458-463.
14 Meng XY, Zhao RG, Shen G, et al. Efficacy and safety of bevacizumab
treatment for refractory brain edema: Case report[J]. Medicine(Baltimore), 2017, 96(44): e8280.
15 Martin R, Joachim von P, Petr Z, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL[J]. J Clin Oncol, 2009, 27(8): 1227-1234.
16 Jyoti DP, Mark AS, Edward BG, et al. Point Break: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31(34): 4349-4357.
17 Motohiro T, Akihiro T, Takayuki S, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations[J]. Invest New Drugs, 2018, 36(4): 608-614.
18 Matthew DH, Jamie EC, Valerie R, et al. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab[J]. Cancer Chemother Pharmacol, 2013, 72(2): 453-461.

备注/Memo

备注/Memo:
通信作者: 杜建飞, Email: 38603287@qq.com
更新日期/Last Update: 2020-10-20